StockTipsArenaBeta

BUY Caplin Point Laboratories Limited — MarketSmith India

BUYCaplin Point Laboratories Limited

byMarketSmith IndiaHorizon: 1–3 months25 Sept 2026via LiveMint Buy-or-Sell (topic)

Entry₹2,859.5Stated
Target₹3,290
Total upside +15.06%
Stop loss₹2,690-5.93% risk
CMP₹2,819.2Just now
Active-1.41%+16.70%upside left 3 mo left
Follow MarketSmith India for new calls(17% target hit, 24 closed calls)Get alertsWatch CAPLIPOINT for new buy/sell callsGet alertsSee 1 other Short-term call on CAPLIPOINTSee 98 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Sept, 2:15 pm IST
5 supporting3 neutral1 opposing
Supports the BUY call (5)

3 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·25 Sept · today

Past month's volume 2.8× the prior month's average

Technicals · volume·24 Sept · yesterday

1 other SEBI-registered advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·24 Sept · yesterday

Caplin Point's Unit Gets Colombia's INVIMA GMP Compliance Nod for Oncology Drugs

NewsGoogle News·5 Sept · 3w ago

(opens in new tab)

Caplin Point Subsidiary Gets Colombian GMP Certification

NewsGoogle News·1 Sept · 3w ago

(opens in new tab)
Neutral / worth noting (3)

Caplin Point Labs schedules AGM with ₹8 per share dividend payout

NewsGoogle News·16 Sept · 1w ago

(opens in new tab)

Caplin Point Labs schedules AGM with ₹8 per share dividend payout

NewsGoogle News·8 Sept · 2w ago

(opens in new tab)

Caplin Point Laboratories: AGM Details and ₹8 Dividend

NewsGoogle News·3 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·25 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.